PRQR

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

ProQR Therapeutics BV

NASDAQ | PRQR

2.91

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 24, 2025)

$306.55M

Market Cap

-

P/E Ratio

-0.46

EPS

$4.21

52 Week High

$1.07

52 Week Low

HEALTHCARE

Sector

PRQR Chart

Recent Chart
Price Action

PRQR Technicals

Tags:

PRQR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $19M
Total Revenue $19M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$30M
Selling General And Administrative $14M
Research And Development $36M
Operating Expenses $49M
Investment Income Net -
Net Interest Income $2.2M
Interest Income $3.3M
Interest Expense $1.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.8M
Income Before Tax -$28M
Income Tax Expense -$197K
Interest And Debt Expense -
Net Income From Continuing Operations -$28M
Comprehensive Income Net Of Tax -
Ebit -$27M
Ebitda -$24M
Net Income -$28M

Revenue & Profitability

Earnings Performance

PRQR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (EUR)
Total Assets $168M
Total Current Assets $154M
Cash And Cash Equivalents At Carrying Value $149M
Cash And Short Term Investments $149M
Inventory -
Current Net Receivables $2M
Total Non Current Assets $14M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments -
Other Current Assets $2.4M
Other Non Current Assets -
Total Liabilities $79M
Total Current Liabilities $39M
Current Accounts Payable $16K
Deferred Revenue -
Current Debt -
Short Term Debt $6.1M
Total Non Current Liabilities $40M
Capital Lease Obligations $13M
Long Term Debt -
Current Long Term Debt $4.6M
Long Term Debt Noncurrent -
Short Long Term Debt Total $17M
Other Current Liabilities $9.3M
Other Non Current Liabilities -
Total Shareholder Equity $89M
Treasury Stock -
Retained Earnings -$427M
Common Stock $4.3M
Common Stock Shares Outstanding $82M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (EUR)
Operating Cashflow -$36M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.8M
Capital Expenditures $1.4M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$4.1M
Cashflow From Financing $70M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$28M

yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $19M
Total Revenue $19M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$30M
Selling General And Administrative $14M
Research And Development $36M
Operating Expenses $49M
Investment Income Net -
Net Interest Income $2.2M
Interest Income $3.3M
Interest Expense $1.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.8M
Income Before Tax -$28M
Income Tax Expense -$197K
Interest And Debt Expense -
Net Income From Continuing Operations -$28M
Comprehensive Income Net Of Tax -
Ebit -$27M
Ebitda -$24M
Net Income -$28M

PRQR News

PRQR Profile

ProQR Therapeutics BV Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

ProQR Therapeutics BV, headquartered in Leiden, the Netherlands, is a pioneering biopharmaceutical firm specializing in RNA-based therapies for severe genetic disorders. The company boasts a robust pipeline, featuring advanced candidates targeting both rare and prevalent diseases, and utilizes its proprietary technology platform to develop innovative solutions that tackle the root causes of these conditions. With a strong commitment to cutting-edge research and development, ProQR is positioned as a significant contributor to the burgeoning field of genetic medicine, dedicated to transforming patient lives through its breakthrough therapeutics.

BYND
-23.06%
$2.18
WGRX
+185.43%
$1.14
VHAI
-50.00%
$0.00
TOVX
+0.87%
$0.34
YYAI
-14.98%
$0.07
VIVK
+11.91%
$0.29
F
+12.15%
$13.84
YDKG
-15.04%
$0.06
ASST
+27.28%
$1.10
INTC
+0.31%
$38.28
BURU
+17.26%
$0.40
CENN
-0.74%
$0.21
DVLT
+52.00%
$3.42
CGBS
-39.47%
$0.03
NVDA
+2.25%
$186.26
BITF
+10.68%
$4.61
TSLA
-3.39%
$433.72
AAL
+7.90%
$13.78
DNN
+2.93%
$2.81
CJET
+27.98%
$0.11
RGTI
-1.90%
$38.84
NEUP
+54.07%
$6.24
ADTX
-28.06%
$0.21
PLUG
+2.43%
$2.95
T
+2.11%
$25.14
RIG
+0.25%
$3.90
SCNX
-39.61%
$1.57
NOK
+2.10%
$6.30
AMD
+7.63%
$252.92
QBTS
+5.11%
$32.65
AXDX
-61.36%
$0.03
ABEV
-0.90%
$2.19
GPUS
+4.19%
$0.40
WTO
-7.14%
$0.06
RF
+1.95%
$24.57
CAN
+7.38%
$1.89
LAES
+22.55%
$7.01
SOFI
+3.31%
$29.01
NEHC
+48.35%
$5.86
NUAI
+48.35%
$5.86
QLGN
+3.11%
$3.64
ONDS
+5.66%
$7.46
GRAB
+2.27%
$5.85
TLRY
+0.67%
$1.49
QS
+14.73%
$16.82
ADAP
-7.57%
$0.06
SNAP
+1.01%
$7.95
CIFR
+19.73%
$20.66
AIRE
-22.42%
$0.76
ETHD
-3.52%
$3.83
JOBY
+2.93%
$16.13
ACHR
+3.48%
$11.29
IONZ
-4.02%
$3.82
RMBL
+60.50%
$3.21
RXRX
+5.41%
$6.04
BAC
+1.56%
$52.57
AMZN
+1.41%
$224.21
NIO
+0.14%
$6.90
AAPL
+1.24%
$262.82
ADD
-25.47%
$0.05
QUBT
-2.57%
$15.53
IREN
+12.60%
$62.90
BTBT
+5.10%
$3.91
RR
+12.17%
$6.08
AMC
-1.46%
$2.69
NVTS
+3.37%
$14.07
SRM
+53.27%
$10.30
PLTR
+2.29%
$184.63
CLOV
+19.37%
$3.82
UUUU
+0.51%
$21.37
BTG
-0.38%
$5.21
DFLI
+13.27%
$1.28
RVPH
+18.99%
$0.67
BBD
0.00%
$3.35
MARA
+1.66%
$19.54
NAKA
+5.66%
$0.84
KDLY
+5.66%
$0.84
APLD
+0.14%
$33.43
CUTR
-10.19%
$0.09
PBR
-0.84%
$11.74
WU
+10.19%
$8.97
GOOGL
+2.70%
$259.92
SOUN
-1.42%
$17.98
WLGS
-5.57%
$0.04
RIVN
-0.84%
$12.98
IONQ
+1.56%
$60.30
VZ
+1.09%
$38.82
PFE
+0.36%
$24.76
WULF
+6.44%
$13.71
LAZR
+31.36%
$2.22
ETWO
0.00%
$3.30
RGTZ
+3.08%
$15.36
SKYQ
+9.15%
$0.50
MU
+5.95%
$219.02
JBLU
0.00%
$4.57
SMCI
+0.77%
$48.29
CLSK
+9.59%
$19.36
WBD
-0.47%
$21.15
LUMN
+3.85%
$8.09
HOOD
+4.06%
$139.79
BYND
-23.06%
$2.18
WGRX
+185.43%
$1.14
VHAI
-50.00%
$0.00
TOVX
+0.87%
$0.34
YYAI
-14.98%
$0.07
VIVK
+11.91%
$0.29
F
+12.15%
$13.84
YDKG
-15.04%
$0.06
ASST
+27.28%
$1.10
INTC
+0.31%
$38.28
BURU
+17.26%
$0.40
CENN
-0.74%
$0.21
DVLT
+52.00%
$3.42
CGBS
-39.47%
$0.03
NVDA
+2.25%
$186.26
BITF
+10.68%
$4.61
TSLA
-3.39%
$433.72
AAL
+7.90%
$13.78
DNN
+2.93%
$2.81
CJET
+27.98%
$0.11
RGTI
-1.90%
$38.84
NEUP
+54.07%
$6.24
ADTX
-28.06%
$0.21
PLUG
+2.43%
$2.95
T
+2.11%
$25.14
RIG
+0.25%
$3.90
SCNX
-39.61%
$1.57
NOK
+2.10%
$6.30
AMD
+7.63%
$252.92
QBTS
+5.11%
$32.65
AXDX
-61.36%
$0.03
ABEV
-0.90%
$2.19
GPUS
+4.19%
$0.40
WTO
-7.14%
$0.06
RF
+1.95%
$24.57
CAN
+7.38%
$1.89
LAES
+22.55%
$7.01
SOFI
+3.31%
$29.01
NEHC
+48.35%
$5.86
NUAI
+48.35%
$5.86
QLGN
+3.11%
$3.64
ONDS
+5.66%
$7.46
GRAB
+2.27%
$5.85
TLRY
+0.67%
$1.49
QS
+14.73%
$16.82
ADAP
-7.57%
$0.06
SNAP
+1.01%
$7.95
CIFR
+19.73%
$20.66
AIRE
-22.42%
$0.76
ETHD
-3.52%
$3.83
JOBY
+2.93%
$16.13
ACHR
+3.48%
$11.29
IONZ
-4.02%
$3.82
RMBL
+60.50%
$3.21
RXRX
+5.41%
$6.04
BAC
+1.56%
$52.57
AMZN
+1.41%
$224.21
NIO
+0.14%
$6.90
AAPL
+1.24%
$262.82
ADD
-25.47%
$0.05
QUBT
-2.57%
$15.53
IREN
+12.60%
$62.90
BTBT
+5.10%
$3.91
RR
+12.17%
$6.08
AMC
-1.46%
$2.69
NVTS
+3.37%
$14.07
SRM
+53.27%
$10.30
PLTR
+2.29%
$184.63
CLOV
+19.37%
$3.82
UUUU
+0.51%
$21.37
BTG
-0.38%
$5.21
DFLI
+13.27%
$1.28
RVPH
+18.99%
$0.67
BBD
0.00%
$3.35
MARA
+1.66%
$19.54
NAKA
+5.66%
$0.84
KDLY
+5.66%
$0.84
APLD
+0.14%
$33.43
CUTR
-10.19%
$0.09
PBR
-0.84%
$11.74
WU
+10.19%
$8.97
GOOGL
+2.70%
$259.92
SOUN
-1.42%
$17.98
WLGS
-5.57%
$0.04
RIVN
-0.84%
$12.98
IONQ
+1.56%
$60.30
VZ
+1.09%
$38.82
PFE
+0.36%
$24.76
WULF
+6.44%
$13.71
LAZR
+31.36%
$2.22
ETWO
0.00%
$3.30
RGTZ
+3.08%
$15.36
SKYQ
+9.15%
$0.50
MU
+5.95%
$219.02
JBLU
0.00%
$4.57
SMCI
+0.77%
$48.29
CLSK
+9.59%
$19.36
WBD
-0.47%
$21.15
LUMN
+3.85%
$8.09
HOOD
+4.06%
$139.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.